Mylan (MYL) calls active after cutting patient cost of EpiPen Auto-Injectors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Mylan's (MYL) EpiPen Saga Could Add More Supply Chain Volatility Moving Forward - Evercore
August 25, 2016 11:46 AM EDTEvercore ISI affirms Mylan (Nasdaq: MYL) with a Hold rating and $49 price target amid today's EpiPen cost-adjustment news.
The firm commented, Thanks to our top rated Specialty Pharma guru Umer Raffat (and CNBC) we are highlighting a slide Mylan is featuring (see below) in its... More
Mylan's (MYL) Steps on EpiPen Do Not Go Far Enough - Wells Fargo's Maris
August 25, 2016 10:33 AM EDTWells Fargo analyst David Maris weighed in on Mylan (NASDAQ: MYL) after the company announced it will expand its existing EpiPen access program with a $300 savings card and increased eligibility, amid mounting political pressure.
Maris said while a good start, these steps do not go far enough to address the underlying issues the Senate and many parents are concerned about, and as such, they believe an FTC investigation and Senate hearings are still a possibility.
The analyst said the steps... More
